Bipolar depression

Summary

Bipolar depression (MONDO:0024613) is a disease and 196 clinical trials. Top therapeutic interventions include lurasidone, valproic acid, and cariprazine. A subtype of depressive disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 196

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bipolar depression
Mondo ID	MONDO:0024613
NCIT	C34424
SNOMED CT	191627008
UMLS	C0005587
MedGen	585
Is cancer (heuristic)	no

Also known as: bipolar affective disorder, current episode depression · bipolar depression

Disease family

This is a subtype of depressive disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › mood disorder › depressive disorder › bipolar depression

Related subtypes (6): seasonal affective disorder, major depressive disorder, melancholia, postpartum depression, neurotic depression, mixed anxiety and depressive disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 196.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	76
PHASE3	38
PHASE2	29
PHASE4	28
PHASE2/PHASE3	8
PHASE1	8
EARLY_PHASE1	5
PHASE1/PHASE2	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06417437	PHASE4	RECRUITING	Non-invasive BCI and Application Verification for Depressed People
NCT07026461	PHASE4	RECRUITING	Right-sided 1-Hz Repetitive Transcranial Magnetic Stimulation (rTMS) Versus Left-sided Intermittent Theta Burst Stimulation (iTBS) in Patients With Depression
NCT07266545	PHASE4	RECRUITING	RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
NCT00198198	PHASE4	COMPLETED	Aripiprazole Treatment of Bipolar Depression
NCT00203528	PHASE4	COMPLETED	Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder
NCT00203567	PHASE4	COMPLETED	Carbamazepine Extended-Release for the Treatment of Bipolar Depression
NCT00305578	PHASE4	COMPLETED	Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression
NCT00363337	PHASE4	COMPLETED	A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression
NCT00384332	PHASE4	COMPLETED	Medication, Weight Gain and GI Hormones
NCT00457054	PHASE4	COMPLETED	Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania
NCT00535262	PHASE4	TERMINATED	A Pilot Study Assessing EmSam in Bipolar Depression
NCT00835120	PHASE4	COMPLETED	Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance
NCT00844857	PHASE4	COMPLETED	A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
NCT00926393	PHASE4	COMPLETED	Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression
NCT01051440	PHASE4	TERMINATED	Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression
NCT01213121	PHASE4	UNKNOWN	Neurophysiologic Changes in Patients With Bipolar Depression
NCT01479829	PHASE4	COMPLETED	Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression
NCT01514422	PHASE4	COMPLETED	Minocycline for Bipolar Depression
NCT01587066	PHASE4	WITHDRAWN	Efficacy of Quetiapine XR Versus Divalproex on Clinical Outcome Quality of Sleep and Quality of Life in Bipolar Depression
NCT01881763	PHASE4	COMPLETED	Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression
NCT01919892	PHASE4	COMPLETED	Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium
NCT02719392	PHASE4	SUSPENDED	A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression
NCT02989727	PHASE4	COMPLETED	Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine
NCT03427892	PHASE4	COMPLETED	Brexpiprazole for Bipolar Depression
NCT03567681	PHASE4	UNKNOWN	Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression
NCT03902613	PHASE4	COMPLETED	18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
NCT05060549	PHASE4	WITHDRAWN	Dopamine D3 Receptor Occupancy in Bipolar Depression
NCT05481957	PHASE4	COMPLETED	Vortioxetine Adjunctive Treatment in Bipolar Depression
NCT04569448	PHASE3	RECRUITING	Brexpiprazole Treatment for Bipolar I Depression
NCT05054699	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Electro-Magnetic Convulsive Therapies for Depression: a Non-inferiority Study
NCT05603104	PHASE3	RECRUITING	Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
NCT05973786	PHASE3	RECRUITING	The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT06372964	PHASE3	RECRUITING	Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT07172516	PHASE3	RECRUITING	A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07217860	PHASE3	ENROLLING_BY_INVITATION	An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
NCT00119652	PHASE3	COMPLETED	Seroquel in Bipolar Depression Versus SSRI
NCT00206141	PHASE3	COMPLETED	Seroquel in Bipolar Depression Versus Lithium
NCT00217217	PHASE3	TERMINATED	Low Field Magnetic Stimulation Treatment for Bipolar Depression
NCT00224510	PHASE3	COMPLETED	A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium
NCT00245973	PHASE3	COMPLETED	Study Evaluating Bifeprunox in Bipolar Depression

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LURASIDONE	4	15
VALPROIC ACID	4	11
CARIPRAZINE	4	6
VENLAFAXINE	4	6
KETAMINE	4	5
LUMATEPERONE	4	5
QUETIAPINE	4	5
BUPROPION	4	4
MINOCYCLINE	4	4
CITALOPRAM	4	3
LAMOTRIGINE	4	3
ARIPIPRAZOLE	4	2
BREXPIPRAZOLE	4	2
LISDEXAMFETAMINE	4	2
METHOHEXITAL	4	2
PAROXETINE	4	2
RILUZOLE	4	2
VORTIOXETINE	4	2
ACETYLCYSTEINE	4	1
ASENAPINE	4	1
CANNABIDIOL	4	1
CEFTRIAXONE	4	1
CELECOXIB	4	1
CLOZAPINE	4	1
ESKETAMINE HYDROCHLORIDE	4	1
GALANTAMINE HYDROBROMIDE	4	1
LITHIUM CARBONATE	4	1
MEMANTINE	4	1
MIDAZOLAM HYDROCHLORIDE	4	1
MIFEPRISTONE	4	1